A Humoral Immune Response Alters the Distribution of Enzyme Replacement Therapy in Murine Mucopolysaccharidosis Type I

作者：Le Steven Q; Kan Shih hsin; Clarke Don; Sanghez Valentina; Egeland Martin; Vondrak Kristen N; Doherty Terence M; Vera Moin U; Iacovino Michelina; Cooper Jonathan D; Sands Mark S; Dickson Patricia I^*

来源：Molecular Therapy-Methods & Clinical Development, 2018, 8: 42-51.

DOI：10.1016/j.omtm.2017.09.008

Antibodies against recombinant proteins can significantly reduce their effectiveness in unanticipated ways. We evaluated the humoral response of mice with the lysosomal storage disease mucopolysaccharidosis type I treated with weekly intravenous recombinant human alpha-L-iduronidase (rhIDU). Unlike patients, the majority of whom develop antibodies to recombinant human alpha-L-iduronidase, only approximately half of the treated mice developed antibodies against recombinant human alpha-L-iduronidase and levels were low. Serum from antibody-positive mice inhibited uptake of recombinant human alpha-Liduronidase into human fibroblasts by partial inhibition compared to control serum. Tissue and cellular distributions of rhIDU were altered in antibody-positive mice compared to either antibody-negative or naive mice, with significantly less recombinant human alpha-L-iduronidase activity in the heart and kidney in antibody-positive mice. In the liver, recombinant human alpha-L-iduronidase was preferentially found in sinusoidal cells rather than in hepatocytes in antibody-positive mice. Antibodies against recombinant human alpha-L-iduronidase enhanced uptake of recombinant human alpha-L-iduronidase into macrophages obtained from MPSI mice. Collectively, these results imply that a humoral immune response against a therapeutic protein can shift its distribution preferentially into macrophage-lineage cells, causing decreased availability of the protein to the cells that are its therapeutic targets.

• 出版日期2018-3
• 单位UCLA